Actively Recruiting

Age: 18Years - 90Years
All Genders
NCT07100457

OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury

Led by Southeast University, China · Updated on 2025-08-03

200

Participants Needed

1

Research Sites

417 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.

CONDITIONS

Official Title

OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Acute myocardial infarction patients with coronary artery disease undergoing primary percutaneous coronary intervention and diagnosed with myocardial ischemia-reperfusion injury after PCI
  • Age 18 to 90 years inclusive
Not Eligible

You will not qualify if you...

  • Active systemic infections
  • Advanced heart failure (NYHA class III-IV)
  • Acute cerebrovascular conditions
  • Active myocarditis
  • Cardiomyopathy
  • Refractory ventricular tachycardia or fibrillation
  • Diagnosis or treatment of malignancy within 5 years (except non-melanoma skin cancer or carcinoma in situ)
  • Severe renal insufficiency (eGFR <30 mL/min/1.73m2 or dialysis dependence)
  • Child-Pugh class C hepatic dysfunction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Cardiology, Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China, 210009

Actively Recruiting

Loading map...

Research Team

W

Wenbin Lu, PhD

CONTACT

Y

Yahao Zhang, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury | DecenTrialz